Dapagliflozin matching placebo

DRUG4 trials

Sponsors

AstraZeneca, Saint Luke's Health System, Klinikum Nürnberg

Conditions

Chronic Heart Failure With Preserved Systolic FunctionChronic Heart Failure With Reduced Systolic FunctionChronic Kidney Disease Stage 3Chronic Renal FailureElectrolyte and Fluid Balance ConditionsMechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte HomeostatisType 2 Diabetes Mellitus

Phase 2

A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.

CompletedNCT05884866

Klinikum NürnbergChronic Kidney Disease Stage 3, Chronic Renal Failure, Electrolyte and Fluid Balance Conditions +1

Start: 2023-07-13End: 2026-01-28Updated: 2026-04-27

Phase 3

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

CompletedNCT00859898

AstraZenecaType 2 Diabetes Mellitus

Start: 2009-04-30End: 2010-05-31Updated: 2016-07-07

Phase 4

Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

CompletedNCT02653482

Saint Luke's Health SystemChronic Heart Failure With Reduced Systolic Function

Start: 2016-03-03End: 2019-06-28Updated: 2022-04-21

Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

CompletedNCT03030235

Saint Luke's Health SystemChronic Heart Failure With Preserved Systolic Function

Start: 2017-03-01End: 2021-08-13Updated: 2022-10-19

Related Papers

Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction

Circulation Heart Failure2024-10-1817 citations

Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The PRESERVED-HF Trial.

2024-04-1715 citations

Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF

Circulation Heart Failure2023-10-2314 citations

Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials

Circulation Heart Failure2023-05-1959 citations

Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF

Circulation2022-05-2389 citations

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Nature Medicine2021-10-28568 citations

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.

2019-09-16312 citations

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.

2019-08-1422 citations

Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study.

2017-08-2323 citations

Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.

2016-11-0114 citations

The effect of dapagliflozin on renal function in patients with type 2 diabetes

Journal of Nephrology2016-02-1977 citations